Compound's dual action inhibits oral cancer without observable side effects

October 19, 2012

The compound licofelone inhibited oral cancer growth by inhibiting the cyclooxygenase and 5-lipoxygenase pathways, with no observable side effects, according to data from a rat study presented at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held here Oct. 16-19, 2012.

(COX) inhibitors have been shown to suppress oral and other cancers, but side effects, such as gastric bleeding, tend to disqualify them as preventive agents. Researchers hypothesized that suppressing COX might instigate cancer-causing inflammation through lipoxygenase (LOX). Because licofelone inhibits both pathways, researchers investigated whether it could provide superior cancer prevention while lowering toxicity.

"Toxicology is always a limitation because you're giving these preventive treatments to otherwise healthy people, so the threshold for toxicity is very low," said lead researcher David McCormick, Ph.D., senior vice president and director at the ITT Research Institute in Chicago. "Dual inhibitors may provide superior chemopreventive activity, as well as a better toxicologic profile."

Using a well-studied rat model, McCormick and colleagues induced oral cancer and tested different licofelone doses, including 37.5 mg/kg per day and 75 mg/kg per day, as well as 75 mg/kg per day after a six-week delay following the induction of cancer.

In a control group, 75 percent of rats developed , the predominant oral cancer in humans, most often at the base of the tongue. They also developed a variety of .

Forty-three percent of rats assigned to high-dose licofelone and 55 percent assigned to the low-dose administration developed cancer. Those assigned to the compound after a six-week delay had a 34 percent incidence of oral cancer. McCormick noted that delayed administration can compromise the in some compounds. The fact that licofelone retained its anticancer action bodes well for its preventive potential, as patients may have already developed precancerous lesions before they seek treatment.

Researchers also observed a decreased incidence of the most advanced (highly invasive) cancers with licofelone: a 17 percent incidence with both doses compared with 54 percent in controls.

Although cancer incidence was reduced in the treated rats, the incidence of precursor lesions increased, again confirming licofelone's ability to suppress the development of , according to the researchers.

"The data suggest the compound inhibits cancer progression," McCormick said. "The lower incidence of invasive cancer and higher incidence of cancer precursors indicate we may be stabilizing progression at the earlier, precancerous stage."

Explore further: Metformin may lower risk for oral cancer development

Related Stories

Metformin may lower risk for oral cancer development

April 2, 2012
New findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research, suggest that metformin may protect against oral cancer.

Strong oral carcinogen identified in smokeless tobacco

April 2, 2012
The chemical (S)-N'-nitrosonornicotine, or (S)-NNN, which is present in smokeless tobacco products, is a strong oral carcinogen, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

Researchers identified markers that predict progression of oral lesions to cancer

August 21, 2012
A group of molecular markers have been identified that can help clinicians determine which patients with low-grade oral premalignant lesions are at high risk for progression to oral cancer, according to data from the Oral ...

Recommended for you

Major study of genetics of breast cancer provides clues to mechanisms behind the disease

October 23, 2017
Seventy-two new genetic variants that contribute to the risk of developing breast cancer have been identified by a major international collaboration involving hundreds of researchers worldwide.

Proton therapy lowers treatment side effects in pediatric head and neck cancer patients

October 23, 2017
Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional photon radiation, and it will result in similar outcomes with less impact on quality of life. Researchers from ...

New study shows how cells can be led down non-cancer path

October 23, 2017
As cells with a propensity for cancer break down food for energy, they reach a fork in the road: They can either continue energy production as healthy cells, or shift to the energy production profile of cancer cells. In a ...

Microbiologists contribute to possible new anti-TB treatment path

October 23, 2017
As part of the long effort to improve treatment of tuberculosis (TB), microbiologists led by Yasu Morita at the University of Massachusetts Amherst report that they have for the first time characterized a protein involved ...

Big Data shows how cancer interacts with its surroundings

October 23, 2017
By combining data from sources that at first seemed to be incompatible, UC San Francisco researchers have identified a molecular signature in tissue adjacent to tumors in eight of the most common cancers that suggests they ...

Symptom burden may increase hospital length of stay, readmission risk in advanced cancer

October 23, 2017
Hospitalized patients with advanced cancer who report more intense and numerous physical and psychological symptoms appear to be at risk for longer hospital stays and unplanned hospital readmissions. The report from a Massachusetts ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.